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Escape from fatal fusion
In 1971, a seminal paper from the laboratory of Philip D’Arcy Hart reported 
that the intracellular pathogen Mycobacterium tuberculosis avoids destruction 
in the cell’s lysosomes by avoiding these organelles altogether—a trick now 
known to be used by many other intracellular pathogens.
At the age of 65, when most people are 
thinking of retiring, Hart was begin-
ning a new phase of his career. As head 
of the MRC Tuberculosis Research 
Unit, London, UK, Hart had already 
become famous for designing what is 
still the definitive format for a clinical 
trial. Now, Hart wanted to understand 
the biology of tuberculosis infection. 
Retirement afforded him the time he 
needed to spend at the bench.
Dodging digestion
It was known that microbes entering 
the body were generally gobbled-up 
and disposed of by roaming macro-
phages. But it was also clear that certain 
microbial pathogens, including M. 
tuberculosis, were able to survive and 
multiply inside these cells, leading to 
prolonged, chronic infection. When 
Hart started his laboratory work at the 
National Institute of Medical Research 
in London, UK, nothing was known 
about how these pathogens survived 
their intracellular fate.
Phagosomes containing inert parti-
cles had been shown to transit from the 
cell surface and fuse with “dense gran-
ules” (lysosomes) (1), and biochemical 
studies had revealed that bacteria could 
be degraded by lysosomal enzymes (2). 
This led Hart to hypothesize two 
possible survival tactics for M. tuberculosis: 
either the bacteria was resistant to lyso-
somal enzymes, or it somehow avoided 
contact with them.
Hart combined electron micros-
copy with the use of an electron-
opaque tracer to mark the lysosomes. 
This novel approach enabled him and 
coworker Johnathan Armstrong to 
report in the Journal of Experimental 
Medicine, in 1971, that M. tuberculosis 
avoids death-by-digestion by remaining 
in a phagosome compartment that is 
separate from the lysosomes (3).
What works for one…
The paper set off a chain of similar 
reports: a year later two groups reported 
similar observations for Chlamydia 
bacteria (4) and the protozoan Toxoplasma 
gondii (5). And by the following decade 
Legionella pneumophila and Encephalitozoon 
cuniculi had joined the list of pathogens 
that escape a lysosomal fate (6, 7).
The paper also marked a turning 
point for cellular microbiology. “Intra-
cellular parasites now weren’t just inside 
cells,” says Marcus Horwitz, University 
of California, Los Angeles. “You could 
now begin to say how their pathways 
differed.” Reports by Horwitz published 
in the Journal of Experimental Medicine 
showed that, whereas L. pneumophila 
establishes its own unique phagosome 
sanctuary, displaying characteristics of 
the rough endoplasmic reticulum (8), 
M. tuberculosis inhibits phagosome 
maturation. Phagosomes normally adopt 
membrane markers of early and then 
late endosomes before finally fusing with 
lysosomes.  M. tuberculosis–containing 
phago  somes, however, halt at the early 
endosome stage (9).
Location matters
Hart’s discovery has also been shaping 
the path of drug and vaccine design. 
David Russell, Cornell University 
College of Veterinary Medicine, New 
York, NY, is interested in designing 
drugs against intracellular pathogens 
and says that, to do so effectively, “you 
have to appreciate the environment in 
which the bacterium finds itself.”
As for vaccines, Horwitz explains 
that the intracellular location of a 
microbe determines the manner in which 
its proteins are displayed to the immune 
system. So when designing a new 
vaccine for M. tuberculosis, Horwitz 
ensured its delivery into phagosomes in 
order to mimic the real bug.
This new vaccine is now being tested 
in human clinical trials—trials which will 
adhere to the rigorous design established 
by Hart in his prelaboratory days.
Philip Montagu D’Arcy Hart (1900–2006)
By sad coincidence Philip D’Arcy Hart 
died on Sunday, July 30, while this 
article was being prepared. Hart’s work 
on cellular microbiology represents a 
small fraction of his extensive contribu-
tion to medical research (10) in a career 
that began in the 1920s and continued, 
with regular visits to the lab, until a few 
years ago.
David Russell, a friend and colleague, 
described Hart as having unrelenting 
energy for science. “He clearly loved 
what he did, and his enthusiasm was 
deeply infectious,” he said. “I still smile 
every time I reference his papers.”
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